A. Significant CAA versus control and CAA versus Alzheimer's disease
|
CLU
|
Clusterin;Clusterin beta chain;Clusterin alpha chain
|
0.000
|
0.000
|
0.001
|
0.007
|
4.47
|
2.33
|
6
|
7
|
7
|
APOE
|
Apolipoprotein E
|
0.001
|
0.001
|
ns
|
ns
|
4.97
|
2.11
|
6
|
7
|
7
|
SUCLG2
|
Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial
|
0.002
|
0.002
|
ns
|
ns
|
2.17
|
0.61
|
5
|
7
|
7
|
PPP2R4
|
Serine/threonine-protein phosphatase 2A activator
|
0.026
|
0.010
|
ns
|
ns
|
2.18
|
0.80
|
6
|
7
|
7
|
KTN1
|
Kinectin
|
0.015
|
0.021
|
ns
|
ns
|
0.34
|
0.40
|
2
|
2
|
3
|
ACTG1
|
Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-terminally processed
|
0.000
|
0.035
|
ns
|
ns
|
0.80
|
0.90
|
6
|
7
|
7
|
TNR
|
Tenascin-R
|
0.007
|
0.017
|
ns
|
ns
|
0.82
|
0.82
|
6
|
7
|
7
|
COL6A3
|
Collagen alpha-3(VI) chain
|
0.016
|
0.024
|
ns
|
ns
|
7.79
|
4.95
|
3
|
5
|
7
|
NFASC
|
Neurofascin
|
0.028
|
0.040
|
ns
|
ns
|
0.86
|
0.87
|
6
|
7
|
7
|
B. Significant CAA versus control or Alzheimer’s disease and ≤1 detection in other group
|
APP
|
Amyloid beta A4 protein;N-APP;Soluble APP-alpha;Soluble APP-beta;
|
NA
|
0.000
|
NA
|
ns
|
NA
|
6.65
|
1
|
7
|
7
|
UBLCP1
|
Ubiquitin-like domain-containing CTD phosphatase 1
|
NA
|
0.007
|
NA
|
ns
|
NA
|
1.96
|
1
|
2
|
4
|
SRI
|
Sorcin
|
NA
|
0.011
|
NA
|
ns
|
NA
|
0.25
|
1
|
3
|
5
|
NDP
|
Norrin
|
NA
|
0.020
|
NA
|
ns
|
NA
|
5.16
|
0
|
4
|
7
|
PNP
|
Purine nucleoside phosphorylase
|
NA
|
0.030
|
NA
|
ns
|
NA
|
1.72
|
0
|
3
|
3
|
C1orf123
|
UPF0587 protein C1orf123
|
NA
|
0.047
|
NA
|
ns
|
NA
|
0.71
|
0
|
6
|
6
|
DHX15
|
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15
|
0.005
|
NA
|
ns
|
NA
|
0.44
|
NA
|
3
|
0
|
5
|
SYNPO
|
Synaptopodin
|
0.015
|
NA
|
ns
|
NA
|
0.44
|
NA
|
4
|
1
|
4
|
TPM1
|
Tropomyosin alpha-1 chain
|
0.021
|
NA
|
ns
|
NA
|
0.37
|
NA
|
3
|
1
|
3
|
CADPS2
|
Calcium-dependent secretion activator 2
|
0.042
|
NA
|
ns
|
NA
|
1.22
|
NA
|
2
|
1
|
3
|
SERPINA3
|
Alpha-1-antichymotrypsin;Alpha-1-antichymotrypsin His-Pro-less
|
0.042
|
NA
|
ns
|
NA
|
−0.86
|
NA
|
2
|
1
|
3
|
C. ≤1 detection in control and Alzheimer's disease and ≥4 in CAA OR ≤1 in CAA and ≥4 in Alzheimer’s disease and control
|
HLA-DRA;HLA-DQA2
|
HLA class II histocompatibility antigen, DR alpha chain;HLA class II histocompatibility antigen, DQ alpha 2 chain
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
0
|
1
|
7
|
HTRA1
|
Serine protease HTRA1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
0
|
1
|
7
|
APCS
|
Serum amyloid P-component;Serum amyloid P-component(1–203)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
0
|
1
|
6
|
COL6A2
|
Collagen alpha-2(VI) chain
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
0
|
1
|
5
|
MOB2
|
MOB kinase activator 2
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
1
|
1
|
5
|
POTEI
|
POTE ankyrin domain family member I
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
1
|
0
|
4
|
KIAA1468
|
LisH domain and HEAT repeat-containing protein KIAA1468
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
1
|
0
|
4
|
TMF1
|
TATA element modulatory factor
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
0
|
1
|
4
|
SGIP1
|
SH3-containing GRB2-like protein 3-interacting protein 1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
4
|
4
|
1
|